# US 2024/0002800 A1 · Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002800 A1
- Document ID: US20240002800A1
- Status: Published application
- Kind: A1
- Application number: 18/197,670
- Filed: 2023-05-15
- Published: 2024-01-04
- Earliest claimed: 2022-05-16
- Assignees: Mendus B.V.
- Applicants: Mendus B.V.
- Inventors: Alex Karlsson-Parra; Erik Hans Manting; Haoxiao Zuo; Satwinder Kaur Singh
- Web page: https://patentgrep.com/patent/US20240002800A1

## CPC

- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/19: Dendritic cells
- A61P 35/00: Antineoplastic agents
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/2315: Interleukin-15 (IL-15)
- C12N 2501/2321: Interleukin-21 (IL-21)
- C12N 2502/1121: Dendritic cells
- C12N 2502/30: tumour cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides ex vivo methods which employ modified cells of leukemic origin to enhance the efficacy of adoptive cell therapy with natural killer (NK) cells.

## Claims

### Claim 1

A method for activating, stimulating and and/or expanding natural killer (NK) cells, comprising:
(a) contacting a population of immune cells substantially comprising natural killer (NK) cells with a population of modified cells of leukemic origin, wherein the modified cells exhibit a mature dendritic cell phenotype; and
(b) co-culturing the population of immune cells with the modified cells of leukemic origin for a period of time such that the modified cell of leukemic origin activates the natural killer (NK) cells in the population of immune cells, thereby generating an expanded population of activated natural killer (NK) cells.

### Claim 2 (depends on 1)

The method of claim 1, where the co-culturing step is performed for a period of about 7 days to about 21 days, about 7 days to about 14 days, or about 14 days.

### Claim 3 (depends on 1)

The method of claim 1, further comprising isolating the expanded population of activated NK cells to generate a purified population of activated NK cells.

### Claim 4 (depends on 1)

The method of claim 1, wherein the NK cells:
1) express NKG2C on their cell surface;
2) are substantially comprised of memory NK cells expressing NKG2C and CD57 on their cell surface;
3) substantially comprise NKG2C+/CD57− precursors of memory NK cells; and/or
4) are low FcεRIγ expression memory NK cells, optionally FcεRIγ negative memory NK cells.

### Claim at position 5

5-8. (canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein:
1) least 70% of the population of immune cells is composed of NK cells; and/or
2) the population of immune cells further comprises T cells, optionally wherein the T cells constitute between 0.01% and 30% of the population of immune cell.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein:
1) the population of the immune cells is co-cultured in the presence of at least one growth factor, optionally, wherein the at least one growth factor is selected from serum, insulin, IFNγ, interleukin-2 (IL-2), IL-4, IL-7, IL-12, IL-15, IL-18, IL-21, GM-CSF, TNF-α, or any combination thereof; or
2) the population of the immune cells are co-cultured in the presence of at least one cytokine, optionally wherein the at least one cytokine is selected from IL-2, IL-15, IL-21, or combinations thereof.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15 (depends on 12)

The method of claim 12, wherein the concentration of IL-2 ranges from about 10 IU/ml to about 6000 IU/mL, the concentration of IL-15 ranges from about 5 ng/mL to about 150 ng/mL.

### Claim 16 (depends on 1)

The method of claim 1, wherein the expanded population of activated NK cells is used for administering to a subject in need thereof.

### Claim 17 (depends on 1)

The method of claim 1, further comprising a step of administering the expanded population of activated NK cells to a subject in need thereof.

### Claim 18 (depends on 17, 116)

The method of claim 116 or claim 17, wherein the population of immune cells are:
1) isolated from peripheral blood mononuclear cells (PBMCs) of the subject;
2) derived from induced pluripotent stem cells (iPSCs) or cord blood; or
3) are isolated from peripheral blood mononuclear cells (PBMCs) of an allogeneic third-party donor different from a subject to receive the expanded population of activated NK cells, optionally wherein the third-party donor is positive for Cytomegalovirus (CMV+).

### Claim at position 16

19-21. (canceled)

### Claim 22 (depends on 1)

The method of claim 1, wherein the NK cells are engineered NK cells, optionally, the engineered NK cells are NK-CAR cells or NK-TCR cells.

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25 (depends on 1)

The method of claim 1, wherein the modified cell of leukemic origin comprises at least one tumor antigen selected from the group consisting of WT-1, RHAMM, PRAME, MUC-1, p53, and Survivin; and/or
wherein the modified cell of leukemic origin is CD34-positive, CD1a-positive, CD83-positive, and CD14-negative.

### Claim 26

(canceled)

### Claim 27 (depends on 1)

The method of claim 1 wherein the modified cell of leukemic origin comprises a co-stimulatory molecule.

### Claim 28 (depends on 27)

The method of claim 27, wherein:
1) the co-stimulatory molecule is selected from an MHC class I molecule, B and T lymphocyte attenuator (BTLA), and a Toll ligand receptor;
2) the co-stimulatory molecule is selected from CD112, CD155, CD70, CD80, CD86, 4-1BBL (CD137-ligand), OX40L, CD30L, CD40, PD-L1, ICOSL, ICAM-1, lymphocyte function-associated antigen 3 (LFA3 (CD58)), K12/SECTM1, LIGHT, HLA-E, B7-H3, and CD83; or
3) the co-stimulatory molecule is selected from CD112, CD155, and/or CD58.

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31 (depends on 1)

The method of claim 1 wherein:
1) the modified cell of leukemic origin further comprises a cell surface marker selected from the group consisting of DC-SIGN, Langerin, CD40, CD70, CD80, CD86, and any combination thereof;
2) the modified cell of leukemic origin is CD70-positive, CD80-positive, and CD86-positive;
3) the modified cell of leukemic origin comprises an MHC class I molecule;
4) the modified cell of leukemic origin comprises an MHC class II molecule; and/or
5) the modified cell of leukemic origin is non-proliferating.

### Claim at position 27

32-35. (canceled)

### Claim 36 (depends on 1)

The method of claim 1, wherein the expanded population of activated NK cells is used for administering to a subject who has been diagnosed with cancer or an infectious disease, optionally wherein the subject has previously been administered an anti-tumor IgG antibody.

### Claim 37

(canceled)

### Claim 38 (depends on 1)

The method of claim 1, wherein the expanded population of activated NK cells increase antibody-dependent cellular cytotoxicity (ADCC); and/or
wherein the expanded population of activated NK cells survive longer after being administered to a subject as compared to a population of NK cells that have not been in contact with the modified cell of leukemic origin prior to administration to a subject.

### Claim 39

(canceled)

### Claim 40 (depends on 22)

The method of claim 22, further comprising a step of introducing a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR) into the NK cells, wherein the CAR or the engineered TCR is introduced to the NK cells prior to, during, or subsequent to co-culturing the population of immune cells with the modified cells of leukemic origin;
optionally wherein the CAR or the engineered TCR is specific for one or more tumor antigens in a subject to receive the expanded population of activated NK cells.

### Claim 41

(canceled)

### Claim 42 (depends on 4)

The method of claim 4, wherein the activation and proliferation of the memory NK cells is effected:
1) in the absence of anti-tumor antibody-opsonized tumor cells; and/or
2) in the absence of cells expressing a ligand for NKG2C on the cell surface of the NK cells, optionally wherein the ligand for NKG2C is HLA-E.

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45 (depends on 1)

The method of claim 1, wherein the expanded population of activated NK cells predominantly comprises
1) NKG2A negative and single killer Ig-like receptor (KIR) positive NK cells; and/or
2) FcεRIγ negative memory NK cells.

### Claim 46

(canceled)
